Advertisement

Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II

      Highlights

      • LDL-C target attainment extremely low for very high-risk CHD and ACS patients.
      • Statin dosages not maximized, with scarce use of combination therapies.
      • Under-treatment of hyperlipidemia on a global scale.

      Abstract

      Background and aims

      Low-density lipoprotein cholesterol (LDL-C) is a major contributor to cardiovascular disease. In the Dyslipidemia International Study II (DYSIS II), we determined LDL-C target value attainment, use of lipid-lowering therapy (LLT), and cardiovascular outcomes in patients with stable coronary heart disease (CHD) and those suffering from an acute coronary syndrome (ACS).

      Methods

      DYSIS II included patients from 18 countries. Patients with either stable CHD or an ACS were enrolled if they were ≥18 years old and had a full lipid profile available. Data were collected at a physician visit (CHD cohort) or at hospital admission and 120 days later (ACS cohort).

      Results

      A total of 10,661 patients were enrolled, 6794 with stable CHD and 3867 with an ACS. Mean LDL-C levels were low at 88 mg/dl and 108 mg/dl for the CHD and ACS cohorts respectively, with only 29.4% and 18.9% displaying a level below 70 mg/dl. LLT was utilized by 93.8% of the CHD cohort, with a mean daily statin dosage of 25 ± 18 mg. The proportion of the ACS cohort treated with LLT rose from 65.2% at admission to 95.6% at follow-up. LLT-treated patients, who were female, obese, or current smokers, were less likely to achieve an LDL-C level of <70 mg/dl, while those with type 2 diabetes, chronic kidney disease, or those taking a higher statin dosage were more likely.

      Conclusions

      Few of these very high-risk patients achieved the LDL-C target, indicating huge potential for improving cardiovascular outcome by use of more intensive LLT.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ramahi T.M.
        Cardiovascular disease in the Asia Middle East region: global trends and local implications.
        Asia Pac J. Public Health. 2010; 22: 83S-89S
        • Kumar A.
        • Cannon C.P.
        Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
        J. Interv. Cardiol. 2007; 20: 447-457
        • Rosa G.M.
        • Carbone F.
        • Parodi A.
        • Massimelli E.A.
        • Brunelli C.
        • Mach F.
        • Vuilleumier N.
        • Montecucco F.
        Update on the efficacy of statin treatment in acute coronary syndromes.
        Eur. J. Clin. Invest. 2014; 44: 501-515
        • Navarese E.P.
        • Kowalewski M.
        • Andreotti F.
        • et al.
        Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
        Am. J. Cardiol. 2014; 113: 1753-1764
        • Lenderink T.
        • Boersma E.
        • Gitt A.K.
        • Zeymer U.
        • Wallentin L.
        • Van de Werf F.
        • Hasdai D.
        • Behar S.
        • Simoons M.L.
        Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes.
        Eur. Heart J. 2006; 27: 1799-1804
        • Spencer F.A.
        • Goldberg R.J.
        • Gore J.M.
        • et al.
        Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein >or=100 mg/dl versus <100 mg/dl.
        Am. J. Cardiol. 2007; 100: 913-918
        • Danchin N.
        • Fauchier L.
        • Marijon E.
        • et al.
        Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register.
        Heart. 2010; 96: 1809-1814
        • European Association for Cardiovascular Prevention & Rehabilitation
        • Reiner Z.
        • Catapano A.L.
        • et al.
        ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
        Eur. Heart J. 2011; 32: 1769-1818
        • Viigimaa M.
        • Erglis A.
        • Latkovskis G.
        • Maeots E.
        • Petrulioniene Z.
        • Slapikas R.
        • Gocentiene A.
        • Bramlage P.
        • Brudi P.
        Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS).
        Med. Kaunas. 2014; 50: 44-53
        • Devroey D.
        • Radermecker R.P.
        • Van der Schueren B.J.
        • Torbeyns B.
        • Jaken R.J.
        Prevalence of persistent lipid abnormalities in statin-treated patients: belgian results of the Dyslipidaemia International Study (DYSIS).
        Int. J. Clin. Pract. 2014; 68: 180-187
        • Al Sifri S.N.
        • Almahmeed W.
        • Azar S.
        • Okkeh O.
        • Bramlage P.
        • Junger C.
        • Halawa I.
        • Ambegaonkar B.
        • Wajih S.
        • Brudi P.
        Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment.
        PLoS One. 2014; 9: e84350
        • Raal F.J.
        • Blom D.J.
        • Naidoo S.
        • Bramlage P.
        • Brudi P.
        Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).
        Cardiovasc J. Afr. 2013; 24: 330-338
        • Reiner Z.
        • De Backer G.
        • Fras Z.
        • Kotseva K.
        • Tokgozoglu L.
        • Wood D.
        • De Bacquer D.
        • Investigators E.
        Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - findings from the EUROASPIRE IV survey.
        Atherosclerosis. 2016; 246: 243-250
        • Catapano A.L.
        • Reiner Z.
        • De Backer G.
        • et al.
        ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
        Atherosclerosis. 2011; 217: 3-46
        • Weng T.C.
        • Yang Y.H.
        • Lin S.J.
        • Tai S.H.
        A systematic review and meta-analysis on the therapeutic equivalence of statins.
        J. Clin. Pharm. Ther. 2010; 35: 139-151
        • Gitt A.
        • Lautsch J.F.
        • Kastelein J.J.
        • Drexel H.
        • Horack M.
        • Brudi P.
        • Van Brabandt H.
        • Bramlage P.
        • Chazelle F.
        • Sazonov V.
        • Ambegaonakr B.M.
        Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
        Atherosclerosis. 2016; 255: 200-209
        • Chiang C.E.
        • Ferrieres J.
        • Gotcheva N.N.
        • Raal F.J.
        • Shehab A.
        • Sung J.
        • Henriksson K.M.
        • Hermans M.P.
        Suboptimal control of lipid levels: results from 29 countries participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS).
        J. Atheroscler. Thromb. 2016 May 2; 23 ([Epub 2015 Dec 2]): 567-587https://doi.org/10.5551/jat.31179
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N. Engl. J. Med. 2015; 372: 2387-2397
        • Baigent C.
        • Keech A.
        • Kearney P.M.
        • Blackwell L.
        • Buck G.
        • Pollicino C.
        • Kirby A.
        • Sourjina T.
        • Peto R.
        • Collins R.
        • Simes R.
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Longenecker J.C.
        • Alfaddagh A.
        • Zubaid M.
        • Rashed W.
        • Ridha M.
        • Alenezi F.
        • Alhamdan R.
        • Akbar M.
        • Bulbanat B.Y.
        • Al-Suwaidi J.
        Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
        Int. J. Cardiol. 2013; 167: 1406-1411
        • Al-Zakwani I.
        • Zubaid M.
        • Panduranga P.
        • Rashed W.
        • Sulaiman K.
        • Almahmeed W.
        • Al-Motarreb A.
        • Al Suwaidi J.
        • Amin H.
        Medication use pattern and predictors of optimal therapy at discharge in 8176 patients with acute coronary syndrome from 6 Middle Eastern countries: data from the gulf registry of acute coronary events.
        Angiology. 2011; 62: 447-454
        • Liosis S.
        • Bauer T.
        • Schiele R.
        • et al.
        Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study.
        Clin. Res. Cardiol. 2013; 102: 671-677
        • Mandelzweig L.
        • Battler A.
        • Boyko V.
        • et al.
        The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004.
        Eur. Heart J. 2006; 27: 2285-2293
        • Amann U.
        • Kirchberger I.
        • Heier M.
        • Goluke H.
        • von Scheidt W.
        • Kuch B.
        • Peters A.
        • Meisinger C.
        Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA Myocardial Infarction Registry.
        Clin. Res. Cardiol. 2014; 103: 655-664
        • Mangiapane S.
        • Busse R.
        Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction: the reality of care revealed by claims data analysis.
        Dtsch. Arztebl Int. 2011; 108: 856-862
        • Zeymer U.
        • Heuer H.
        • Schwimmbeck P.
        • Genth-Zotz S.
        • Wolff K.
        • Nienaber C.A.
        Guideline-adherent therapy in patients with acute coronary syndromes. The EPICOR registry in Germany.
        Herz. 2015; 40: 27-35
        • Karlson B.W.
        • Wiklund O.
        • Palmer M.K.
        • Nicholls S.J.
        • Lundman P.
        • Barter P.J.
        Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.
        Eur. Heart J. Cardiovasc Pharmacother. 2016; 2: 212-217
        • Stroes E.S.
        • Thompson P.D.
        • Corsini A.
        • et al.
        Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management.
        Eur. Heart J. 2015; 36: 1012-1022
        • Jackevicius C.A.
        • Mamdani M.
        • Tu J.V.
        Adherence with statin therapy in elderly patients with and without acute coronary syndromes.
        JAMA. 2002; 288: 462-467
        • Benner J.S.
        • Glynn R.J.
        • Mogun H.
        • Neumann P.J.
        • Weinstein M.C.
        • Avorn J.
        Long-term persistence in use of statin therapy in elderly patients.
        JAMA. 2002; 288: 455-461
        • Mann D.M.
        • Woodward M.
        • Muntner P.
        • Falzon L.
        • Kronish I.
        Predictors of nonadherence to statins: a systematic review and meta-analysis.
        Ann. Pharmacother. 2010; 44: 1410-1421
        • Gitt A.K.
        • Drexel H.
        • Feely J.
        • et al.
        Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
        Eur. J. Prev. Cardiol. 2012; 19: 221-230
        • Krauss R.M.
        Lipids and lipoproteins in patients with type 2 diabetes.
        Diabetes Care. 2004; 27: 1496-1504
        • Taskinen M.R.
        • Boren J.
        New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
        Atherosclerosis. 2015; 239: 483-495
        • Vaziri N.D.
        Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.
        Am. J. Physiol. Ren. Physiol. 2006; 290: F262-F272
        • Abtan J.
        • Bhatt D.L.
        • Elbez Y.
        • et al.
        Residual ischemic risk and its determinants in patients with previous myocardial infarction and without prior stroke or TIA: insights from the REACH registry.
        Clin. Cardiol. 2016 Nov; 39 ([Epub 2016 Sep 2]): 670-677https://doi.org/10.1002/clc.22583